Incidence and risk of severe infections associated with aflibercept in cancer patients: a systematic review and meta-analysis

British Journal of Clinical Pharmacology
Xi ZhangYuanxue Zhu

Abstract

Aflibercept is an engineered humanized vascular endothelial growth factor (VEGF)-targeted agent. Severe infections are serious adverse event associated with aflibercept. However, the contribution of aflibercept to infection is still unknown. We thus conducted this meta-analysis to investigate the overall incidence and risk of developing severe infections in cancer patients treated with aflibercept. Electronic databases including PubMed, Embase and abstracts presented at American Society of Clinical Oncology (ASCO) and European Society of Medical Oncology (ESMO) meeting were searched. Eligible studies were phase II and III prospective clinical trials of aflibercept in cancer patients with toxicity profile on infections. Summary incidences, relative risk (RR), odds ratio (OR) and 95% confidence intervals (95% CIs) were calculated by using either random effects or fixed effect models according to the heterogeneity of included studies. A total of 4310 patients with a variety of solid tumours from 10 prospective clinical trials were included in the meta-analysis. The incidence of high grade infections associated with aflibercept was 7.3% (95% CI 4.3, 12.0%), with a mortality of 2.2% (95% CI 1.5, 3.1%). In addition, patients treated ...Continue Reading

References

Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Aug 15, 2002·Proceedings of the National Academy of Sciences of the United States of America·Jocelyn HolashJohn S Rudge
Jan 8, 2003·Seminars in Oncology·Judah Folkman
Apr 30, 2004·Statistics in Medicine·Michael J SweetingPaul C Lambert
Dec 9, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel J Hicklin, Lee M Ellis
Dec 14, 2004·Genetic Epidemiology·Elias Zintzaras, John P A Ioannidis
Jul 2, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Natasha B LeighlRoy S Herbst
Aug 5, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Sergey V NovitskiyMikhail M Dikov
Feb 23, 2011·Critical Reviews in Oncology/hematology·Fabio A B SchutzToni K Choueiri
Apr 8, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Fabio A B SchutzToni K Choueiri
Sep 12, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rodryg RamlauGiorgio Scagliotti
Oct 10, 2012·The Journal of Experimental Medicine·Wiebke HansenIris Helfrich
May 7, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Philippe RougierPhilip A Philip
Jun 25, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ling PengQiong Zhao
Jul 9, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey W AllenDavid R Gandara
Jul 30, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Wei-Xiang QiGuo Xiao-Mao
Sep 10, 2014·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sukhbir KaurDavid D Roberts

❮ Previous
Next ❯

Citations

May 4, 2016·Cirugia y cirujanos·Estíbaliz Echazarreta-GallegoElena Córdoba-Díaz de Laspra
Aug 5, 2017·Annals of the Royal College of Surgeons of England·A Gonzaga-LópezA Ruiz-Casado
Mar 9, 2021·Therapeutic Advances in Infectious Disease·Isabel Ruiz-Camps, Juan Aguilar-Company

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.